pentobarbital will reduce the extent or effect of trazodone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital raises effects of ifosfamide by impacting hepatic enzyme CYP2B6 metabolism. Use Caution/Watch. Coadministration of ifosfamide with CYP2B6 inducers might increase metabolism of ifosfamide to its metabolite. Check for greater effects/toxicities if mixed with CYP2B6 inducers.
pentobarbital will lower the level or result of naloxegol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Use of naloxegol with powerful CYP3A4 inducers is not advised
pentobarbital will minimize the extent or effect of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.
Constantly monitor vital symptoms all through sedation and recovery period of time if coadministered. Cautiously titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
pentobarbital decreases levels of panobinostat by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Solid CYP3A4 inducers can lower panobinostat degrees by ~70% and bring on procedure failure.
pentobarbital will decrease the level or outcome of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not suggested; solid cytochrome P450 enzyme inducers reduce systemic exposure to roflumilast and will lessen the therapeutic effectiveness
pentobarbital will minimize the level or result of etravirine by impacting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Keep track of.
pentobarbital will lower the extent or impact of colchicine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will minimize the level or influence of cevimeline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. click here Insignificant/Importance Mysterious.
pentobarbital will reduce the level or outcome of alfentanil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unfamiliar.
pentobarbital will decrease the level or result of buprenorphine, very long-acting injection by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Intently. Clients who transfer to buprenorphine extended-performing injection from transmucosal buprenorphine coadministered with CYP3A4 inducers ought to be monitored to ensure buprenorphine plasma stages are sufficient.
Soon after halting a CYP3A4 inducer, because the effects of the inducer decrease, the fentanyl plasma concentration will improve which could maximize or prolong both the therapeutic and adverse effects.
Contraindicated (one)pentobarbital decreases levels of vandetanib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration with strong CYP3A4 inducers; these drugs lower exposure to vandetanib by as much as 40%.